Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.68
<$0.01(0.15%)
At close: 4:00 PM EST
$1.68
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume1.63M
Average Volume (3M)13.36M
Market Cap
$962.28M
Enterprise Value$970.13M
Total Cash (Recent Filing)$314.29M
Total Debt (Recent Filing)$251.84M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 06, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding641,521,000
10 Day Avg. Volume10,601,811
30 Day Avg. Volume13,360,350
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue4.95
Enterprise Value/Gross Profit5.71
Enterprise Value/Ebitda-26.26
Forecast
1Y Price Target
$4.00Price Target Upside138.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$233.75M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & 2026 GuidanceSustained double-digit top-line growth and reiterated full-year revenue guidance reflect durable commercial scale-up. Predictable revenue targets improve planning for manufacturing and marketing, support operating leverage potential, and reduce execution risk over the next 2–6 months.
Commercial Traction And AdoptionQuarterly demand growth, rising prescriber count and increasing early-line use indicate widening clinical adoption. A growing base of prescribing accounts and higher share of early-line starts create a more durable revenue foundation and lower concentration risk for future quarters.
Clinical Validation & Pipeline CatalystsA fully enrolled Phase III with an upcoming interim and peer-reviewed publications materially de-risks the scientific case and supports medical adoption. Demonstrated clinical validation and NCCN inclusion strengthen long-term market positioning and payer engagement prospects.
Bears Say
Persistent Cash BurnMaterial negative operating and free cash flow implies the company will need liquidity from existing reserves or external financing if trends persist. Ongoing burn constrains strategic flexibility, increases financing risk, and can limit investment in commercialization or supply over the medium term.
Widening Gross-to-Net PressureSustained higher gross-to-net deductions (340B utilization, GPO contracting) reduce realized revenue per unit and compress margins. Structural pressure on net pricing hampers scalability of revenue growth and makes forecasting and margin recovery more difficult over upcoming reporting periods.
Clinical Outcome UncertaintyA blinded interim represents a binary clinical risk: an unfavorable or neutral read could materially slow adoption and impair read-through to related indications. This uncertainty over trial outcome is a durable fundamental risk until definitive results are reported.
Geron News
GERN FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $962.28M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 23 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on May 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.01.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 641,521,000 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (138.10% Upside)
$4.00 (138.10% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.69%
12-Months-Change
Fundamentals
Return on Equity
-28.90%
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Stock 12 Month Forecast
Average Price Target
$4.00
▲(138.10% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
11.33% Mutual Funds
0.23% Other Institutional Investors
72.91% Public Companies and
Individual Investors